First Manhattan CO Otonomy, Inc. Transaction History

First Manhattan CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$2.49 - $6.23 $4.86 Million - $12.1 Million	-1,949,963 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$3.16 - $4.36 $2.78 Million - $3.84 Million	881,030 Added 82.42%	1,949,963 $7.9 Million
Q2 2020 Aug 14, 2020	BUY	$1.87 - $3.84 $121,550 - $249,600	65,000 Added 6.47%	1,068,933 $3.87 Million
Q1 2020 May 06, 2020	SELL	$1.58 - $4.06 $898,704 - $2.31 Million	-568,800 Reduced 36.17%	1,003,933 $1.98 Million
Q4 2019 Feb 13, 2020	SELL	$2.13 - $3.83 $2.69 Million - $4.84 Million	-1,262,900 Reduced 44.54%	1,572,733 $6.02 Million
Q3 2019 Nov 13, 2019	SELL	$2.12 - $2.86 $218,360 - $294,580	-103,000 Reduced 3.51%	2,835,633 $6.78 Million
Q2 2019 Aug 16, 2019	SELL	$2.35 - $3.09 $101,050 - $132,870	-43,000 Reduced 1.44%	2,938,633 $8.08 Million
Q1 2019 Apr 12, 2019	SELL	$1.8 - $2.97 $108,289 - $178,678	-60,161 Reduced 1.98%	2,981,633 $7.84 Million
Q4 2018 Jan 30, 2019	BUY	$1.51 - $2.93 $1.92 Million - $3.72 Million	1,269,921 Added 71.67%	3,041,794 $5.63 Million
Q3 2018 Oct 15, 2018	SELL	$2.6 - $3.95 $338,330 - $514,001	-130,127 Reduced 6.84%	1,771,873 $4.87 Million
Q4 2017 Jan 22, 2018	BUY	$2.8 - $5.55 $5.33 Million - $10.6 Million	1,902,000	1,902,000 $10.6 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.